Was Angelina Jolie Right? Optimizing Cancer Prevention Strategies Among BRCA Mutation Carriers

References

• Abdollahian M, Das TK (2015) A MDP model for breast and ovarian cancer intervention strategies for BRCA1/2 mutation carriers. IEEE J. Biomedical Health Informatics 19(2):720–727.Crossref, Google Scholar
• Alagoz O, Chhatwal J, Burnside ES (2013) Optimal policies for reducing unnecessary follow-up mammography exams in breast cancer diagnosis. Decision Anal. 10(3):200–224.Link, Google Scholar
• Alagoz O, Hsu H, Schaefer AJ, Roberts MS (2010) Markov decision processes: A tool for sequential decision making under uncertainty. Medical Decision Making 30(4):474–483.Crossref, Google Scholar
• Alagoz O, Maillart LM, Schaefer AJ, Roberts MS (2004) The optimal timing of living-donor liver transplantation. Management Sci. 50(10):1420–1430.Link, Google Scholar
• Anderson K, Jacobson JS, Heitjan DF, Zivin JG, Hershman D, Neugut AI, Grann VR (2006) Cost-effectiveness of preventive strategies for women with a BRCA1 or a BRCA2 mutation. Ann. Internal Medicine 144(6):397–406.Crossref, Google Scholar
• Antoniou A, Pharoah PD, Narod S, Risch HA, Eyfjord JE, Hopper JL, Loman N, et al. (2003) Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history: A combined analysis of 22 studies. Amer. J. Human Genetics 72(5):1117–1130.Crossref, Google Scholar
• Armstrong K, Schwartz JS, Randall T, Rubin SC, Weber B (2004) Hormone replacement therapy and life expectancy after prophylactic oophorectomy in women with BRCA1/2 mutations: A decision analysis. J. Clinical Oncology 22(6):1045–1054.Crossref, Google Scholar
• Asakawa K, Senthilselvan A, Feeny D, Johnson J, Rolfson D (2012) Trajectories of health-related quality of life differ by age among adults: Results from an eight-year longitudinal study. J. Health Econom. 31(1):207–218.Crossref, Google Scholar
• Ayer T, Alagoz O, Stout NK (2012) OR Forum—A POMDP approach to personalize mammography screening decisions. Oper. Res. 60(5):1019–1034.Link, Google Scholar
• Barlow RE, Proschan F (1965) Mathematical Theory of Reliability (John Wiley & Sons, New York).Google Scholar
• Barton MB, West CN, Liu ILA, Harris EL, Rolnick SJ, Elmore JG, Herrinton LJ, et al. (2005) Complications following bilateral prophylactic mastectomy. JNCI Monographs 2005(35):61–66.Crossref, Google Scholar
• Bolton KL, Chenevix-Trench G, Goh C, Sadetzki S, Ramus SJ, Karlan BY, Lambrechts D, et al. (2012) Association between BRCA1 and BRCA2 mutations and survival in women with invasive epithelial ovarian cancer. J. Amer. Medical Assoc. 307(4):382.Crossref, Google Scholar
• Breastcancer.org (2017) U.S. breast cancer statistics. Accessed June 15, 2017, http://www.breastcancer.org/symptoms/understand_bc/statistics.Google Scholar
• Brown M, Tsodikov A, Bauer KR, Parise CA, Caggiano V (2008) The role of human epidermal growth factor receptor 2 in the survival of women with estrogen and progesterone receptor-negative, invasive breast cancer: The California Cancer Registry, 1999–2004. Cancer 112(4):737–747.Crossref, Google Scholar
• Centers for Disease Control and Prevention (CDC) (2014) Underlying cause of death 1999–2015. CDC WONDER online database, released 2015. Accessed June 15, 2017, http://wonder.cdc.gov/ucd-icd10.html.Google Scholar
• Chen S, Parmigiani G (2007) Meta-analysis of BRCA1 and BRCA2 penetrance. J. Clinical Oncology 25(11):1329–1333.Crossref, Google Scholar
• Chhatwal J, Alagoz O, Burnside ES (2010) Optimal breast biopsy decision-making based on mammographic features and demographic factors. Oper. Res. 58(6):1577–1591.Link, Google Scholar
• de Farias DP, van Roy B (2003) The linear programming approach to approximate dynamic programming. Oper. Res. 51(6):850–865.Link, Google Scholar
• Domchek SM, Friebel TM, Neuhausen SL, Wagner T, Evans G, Isaacs C, Garber JE, et al. (2006) Mortality after bilateral salpingo-oophorectomy in BRCA1 and BRCA2 mutation carriers: A prospective cohort study. Lancet Oncology 7(3):223–229.Crossref, Google Scholar
• Domchek SM, Friebel TM, Singer CF, Evans DG, Lynch HT, Isaacs C, Garber JE, et al. (2010) Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality. J. Amer. Medical Assoc. 304(9):967–975.Crossref, Google Scholar
• Duffy SW, Nixon RM (2002) Estimates of the likely prophylactic effect of tamoxifen in women with high risk BRCA1 and BRCA2 mutations. British J. Cancer 86(2):218–221.Crossref, Google Scholar
• Edge SB, Compton CC (2010) The American Joint Committee on Cancer: The 7th edition of the AJCC cancer staging manual and the future of TNM. Ann. Surgical Oncology 17(6):1471–1474.Crossref, Google Scholar
• Eisen A, Lubinski J, Klijn J, Moller P, Lynch HT, Offit K, Weber B, et al. (2005) Breast cancer risk following bilateral oophorectomy in BRCA1 and BRCA2 mutation carriers: An international case-control study. J. Clinical Oncology 23(30):7491–7496.Crossref, Google Scholar
• Evans DG, Wisely J, Clancy T, Lalloo F, Wilson M, Johnson R, Duncan J, et al. (2015) Longer term effects of the Angelina Jolie effect: Increased risk-reducing mastectomy rates in BRCA carriers and other high-risk women. Breast Cancer Res. 17:143.Crossref, Google Scholar
• Evans DG, Barwell J, Eccles DM, Collins A, Izatt L, Jacobs C, Donaldson A, et al. (2014) The Angelina Jolie effect: How high celebrity profile can have a major impact on provision of cancer related services. Breast Cancer Res. 16:442.Crossref, Google Scholar
• Fry A, Busby-Earle C, Rush R, Cull A (2001) Prophylactic oophorectomy versus screening: Psychosocial outcomes in women at increased risk of ovarian cancer. Psycho-Oncology 10(3):231–241.Crossref, Google Scholar
• Garcia C, Wendt J, Lyon L, Jones J, Littell RD, Armstrong MA, Raine-Bennett T, et al. (2014) Risk management options elected by women after testing positive for a BRCA mutation. Gynecologic Oncology 132(2):428–433.Crossref, Google Scholar
• Gass SI (1983) Decision-aiding models: Validation, assessment, and related issues for policy analysis. Oper. Res. 31(4):603–631.Link, Google Scholar
• Geiger AM, West CN, Nekhlyudov L, Herrinton LJ, Liu IL, Altschuler A, Rolnick SJ, et al. (2006) Contentment with quality of life among breast cancer survivors with and without contralateral prophylactic mastectomy. J. Clinical Oncology 24(9):1350–1356.Crossref, Google Scholar
• Graeser MK, Engel C, Rhiem K, Gadzicki D, Bick U, Kast K, Froster UG, et al. (2009) Contralateral breast cancer risk in BRCA1 and BRCA2 mutation carriers. J. Clinical Oncology 27(35):5887–5892.Crossref, Google Scholar
• Grann VR, Panageas KS, Whang W, Antman KH, Neugut AI (1998) Decision analysis of prophylactic mastectomy and oophorectomy in BRCA1-positive or BRCA2-positive patients. J. Clinical Oncology 16(3):979–985.Crossref, Google Scholar
• Grann VR, Jacobson JS, Sundararajan V, Albert SM, Troxel AB, Neugut AI (1999a) The quality of life associated with prophylactic treatments for women with BRCA1/2 mutations. Cancer J. Sci. Amer. 5(5):283–292.Google Scholar
• Grann VR, Jacobson JS, Thomason D, Hershman D, Heitjan DF, Neugut AI (2002) Effect of prevention strategies on survival and quality-adjusted survival of women with BRCA1/2 mutations: An updated decision analysis. J. Clinical Oncology 20(10):2520–2529.Crossref, Google Scholar
• Grann VR, Whang W, Jacobson JS, Heitjan DF, Antman KH, Neugut AI (1999b) Benefits and costs of screening Ashkenazi Jewish women for BRCA1 and BRCA2. J. Clinical Oncology 17(2):494–500.Crossref, Google Scholar
• Grann VR, Patel P, Bharthuar A, Jacobson JS, Warner E, Anderson K, Warner E, et al. (2010) Breast cancer-related preferences among women with and without BRCA mutations. Breast Cancer Res. Treatment 119(1):177–184.Crossref, Google Scholar
• Grant RL (2014) Converting an odds ratio to a range of plausible relative risks for better communication of research findings. British Medical J. 348(January):1–7.Google Scholar
• Hall JM, Lee MK, Newman B, Morrow JE, Anderson LA, Huey B, King MC (1990) Linkage of early-onset familial breast cancer to chromosome 17q21. Science 250(4988):1684–1689.Crossref, Google Scholar
• Hall MJ, Reid JE, Burbidge LA, Pruss D, Deffenbaugh AM, Frye C, Wenstrup RJ, et al. (2009) BRCA1 and BRCA2 mutations in women of different ethnicities undergoing testing for hereditary breast–ovarian cancer. Cancer 115(10):2222–2233.Crossref, Google Scholar
• Harmsen MG, Hermens RP, Prins JB, Hoogerbrugge N, de Hullu JA (2015) How medical choices influence quality of life of women carrying a BRCA mutation. Critical Rev. Oncology/Hematology 96(3):555–568.Crossref, Google Scholar
• Hartmann LC, Sellers TA, Schaid DJ, Frank TS, Soderberg CL, Sitta DL, Frost MH, et al. (2001) Efficacy of bilateral prophylactic mastectomy in BRCA1 and BRCA2 gene mutation carriers. J. Natl. Cancer Inst. 93(21):1633–1637.Crossref, Google Scholar
• Hayes DF (2017) Patient education: Treatment of metastatic breast cancer (beyond the basics). Accessed June 15, 2017, http://www.uptodate.com/contents/treatment-of-metastatic-breast-cancer-beyond-the-basics.Google Scholar
• John EM, Miron A, Gong G, Phipps AI, Felberg A, Li FP, West DW, et al. (2007) Prevalence of pathogenic BRCA1 mutation carriers in 5 US racial/ethnic groups. J. Amer. Medical Assoc. 298(24):2869–2876.Crossref, Google Scholar
• Jolie A (2013) My medical choice. New York Times (May 14), http://www.nytimes.com/2013/05/14/opinion/my-medical-choice.html.Google Scholar
• Jolie A (2015) Diary of a surgery. New York Times (March 24), https://www.nytimes.com/2015/03/24/opinion/angelina-jolie-pitt-diary-of-a-surgery.html.Google Scholar
• Karami F, Mehdipour P (2013) A comprehensive focus on global spectrum of BRCA1 and BRCA2 mutations in breast cancer. BioMed Res. Internat. 2013:928562.Crossref, Google Scholar
• Kauff ND, Domchek SM, Friebel TM, Robson ME, Lee J, Garber JE, Isaacs C, et al. (2008) Risk-reducing salpingo-oophorectomy for the prevention of BRCA1- and BRCA2-associated breast and gynecologic cancer: A multicenter, prospective study. J. Clinical Oncology 26(8):1331–1337.Crossref, Google Scholar
• King MC, Wieand S, Hale K, Lee M, Walsh T, Owens K, Tait J, et al. (2001) Tamoxifen and breast cancer incidence among women with inherited mutations in BRCA1 and BRCA2: National Surgical Adjuvant Breast and Bowel Project (NSABP-P1) Breast Cancer Prevention Trial. J. Amer. Medical Assoc. 286(18):2251–2256.Crossref, Google Scholar
• Kurian AW, Sigal BM, Plevritis SK (2010) Survival analysis of cancer risk reduction strategies for BRCA1/2 mutation carriers. J. Clinical Oncology 28(2):222–231.Crossref, Google Scholar
• Kurian AW, Lichtensztajn DY, Keegan THM, Nelson DO, Clarke CA, Gomez SL (2014) Use of and mortality after bilateral mastectomy compared with other surgical treatments for breast cancer in California, 1998–2011. J. Amer. Medical Assoc. 312(9):902–914.Crossref, Google Scholar
• Kurian AW, Munoz DF, Rust P, Schackmann EA, Smith M, Clarke L, Mills MA, et al. (2012) Online tool to guide decisions for BRCA1/2 mutation carriers. J. Clinical Oncology 30(5):497–506.Crossref, Google Scholar
• Lambrou NC, Bristow RE (2003) Ovarian cancer in elderly women. Oncology 17(8):1075–1081.Google Scholar
• Lee LJ, Alexander B, Schnitt SJ, Comander A, Gallagher B, Garber JE, Tung N (2011) Clinical outcome of triple negative breast cancer in BRCA1 mutation carriers and noncarriers. Cancer 117(14):3093–3100.Crossref, Google Scholar
• Lobbezoo DJA, van Kampen RJW, Voogd AC, Dercksen MW, van den Berkmortel F, Smilde TJ, van de Wouw AJ, et al. (2015) Prognosis of metastatic breast cancer: Are there differences between patients with de novo and recurrent metastatic breast cancer? British J. Cancer 112(9):1445–1451.Crossref, Google Scholar
• Long EF, Ganz PA (2015) Cost-effectiveness of universal BRCA1/2 screening: Evidence-based decision making. JAMA Oncology 1(9):1217–1218.Crossref, Google Scholar
• Madalinska JB, Hollenstein J, Bleiker E, van Beurden M, Valdimarsdottir HB, Massuger LF, Gaarenstroom KN, et al. (2005) Quality-of-life effects of prophylactic salpingo-oophorectomy versus gynecologic screening among women at increased risk of hereditary ovarian cancer. J. Clinical Oncology 23(28):6890–6898.Crossref, Google Scholar
• Mavaddat N, Barrowdale D, Andrulis IL, Domchek SM, Eccles D, Nevanlinna H, Ramus SJ, et al. (2012) Pathology of breast and ovarian cancers among BRCA1 and BRCA2 mutation carriers: Results from the consortium of investigators of modifiers of BRCA1/2 (CIMBA). Cancer Epidemiology, Biomarkers Prevention 21(1):134–147.Crossref, Google Scholar
• McDonnell SK, Schaid DJ, Myers JL, Grant CS, Donohue JH, Woods JE, Frost MH, et al. (2001) Efficacy of contralateral prophylactic mastectomy in women with a personal and family history of breast cancer. J. Clinical Oncology 19(19):3938–3943.Crossref, Google Scholar
• Metcalfe KA, Lynch HT, Ghadirian P, Tung N, Olivotto IA, Foulkes WD, Warner E, et al. (2005) The risk of ovarian cancer after breast cancer in BRCA1 and BRCA2 carriers. Gynecologic Oncology 96(1):222–226.Crossref, Google Scholar
• Michelsen TM, Dørum A, Tropé CG, Fosså SD, Dahl AA (2009) Fatigue and quality of life after risk-reducing salpingo-oophorectomy in women at increased risk for hereditary breast-ovarian cancer. Internat. J. Gynecological Cancer 19(6):1029–1036.Crossref, Google Scholar
• Missmer SA, Eliassen AH, Barbieri RL, Hankinson SE (2004) Endogenous estrogen, androgen, and progesterone concentrations and breast cancer risk among postmenopausal women. J. Natl. Cancer Inst. 96(24):1856–1865.Crossref, Google Scholar
• National Comprehensive Cancer Network (2016) NCCN clinical practice guidelines in oncology. Genetic/familial assessment: Breast and ovarian. Accessed June 15, 2017, https://www.nccn.org/professionals/physician_gls/pdf/genetics_screening.pdf.Google Scholar
• Nilsson MP, Hartman L, Kristoffersson U, Johannsson OT, Borg Å, Henriksson K, Lanke E, et al. (2014) High risk of in-breast tumor recurrence after BRCA1/2-associated breast cancer. Breast Cancer Res. Treatment 147(3):571–578.Crossref, Google Scholar
• Parise CA, Caggiano V (2014) Breast cancer survival defined by the ER/PR/HER2 subtypes and a surrogate classification according to tumor grade and immunohistochemical biomarkers. J. Cancer Epidemiology 2014(2):469251.Google Scholar
• Powell WB (2011) Approximate Dynamic Programming: Solving the Curses of Dimensionality, 2nd ed. (John Wiley & Sons, Hoboken, NJ).Crossref, Google Scholar
• Puterman ML (2014) Markov Decision Processes: Discrete Stochastic Dynamic Programming (John Wiley & Sons, Hoboken, NJ).Google Scholar
• Rebbeck TR, Kauff ND, Domchek SM (2009) Meta-analysis of risk reduction estimates associated with risk-reducing salpingo-oophorectomy in BRCA1 or BRCA2 mutation carriers. J. Natl. Cancer Inst. 101(2):80–87.Crossref, Google Scholar
• Rebbeck TR, Friebel T, Lynch HT, Neuhausen SL, van’t Veer L, Garber JE, Evans GR, et al. (2004) Bilateral prophylactic mastectomy reduces breast cancer risk in BRCA1 and BRCA2 mutation carriers: The PROSE Study Group. J. Clinical Oncology 22(6):1055–1062.Crossref, Google Scholar
• Robson ME, Chappuis PO, Satagopan J, Wong N, Boyd J, Goffin JR, Hudis C, et al. (2003) A combined analysis of outcome following breast cancer: Differences in survival based on BRCA1/BRCA2 mutation status and administration of adjuvant treatment. Breast Cancer Res. 6(1):14680495.Crossref, Google Scholar
• Salhab M, Bismohun S, Mokbel K (2010) Risk-reducing strategies for women carrying BRCA1/2 mutations with a focus on prophylactic surgery. BMC Women’s Health 10:28.Crossref, Google Scholar
• Sargent GR (2013) Verification and validation of simulation models. J. Simulation 7(1):12–24.Crossref, Google Scholar
• Schrag D, Kuntz KM, Garber JE, Weeks JC (2000) Life expectancy gains from cancer prevention strategies for women with breast cancer and BRCA1 or BRCA2 mutations. J. Amer. Medical Assoc. 283(5):617–624.Crossref, Google Scholar
• Schrag D, Kuntz KM, Garber JE, Weeks JC (1997) Decision analysis—Effects of prophylactic mastectomy and oophorectomy on life expectancy among women with BRCA1 or BRCA2 mutations. New England J. Medicine 336(20):1465–1471.Crossref, Google Scholar
• Shuster LT, Gostout BS, Grossardt BR, Rocca WA (2008) Prophylactic oophorectomy in premenopausal women and long-term health. Menopause Internat. 14(3):111–116.Crossref, Google Scholar
• Sørlie T, Tibshirani R, Parker J, Hastie T, Marron JS, Nobel A, Deng S, et al. (2003) Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc. Natl. Acad. Sci. USA 100(14):8418–8423.Crossref, Google Scholar
• Tengs TO, Wallace A (2000) One thousand health-related quality-of-life estimates. Medical Care 38(6):583–637.Crossref, Google Scholar
• Tercyak KP, Peshkin BN, Brogan BM, DeMarco T, Pennanen MF, Willey SC, Magnant CM, et al. (2007) Quality of life after contralateral prophylactic mastectomy in newly diagnosed high-risk breast cancer patients who underwent BRCA1/2 gene testing. J. Clinical Oncology 25(3):285–291.Crossref, Google Scholar
• Toniolo PG, Levitz M, Zeleniuch-Jacquotte A, Banerjee S, Koenig KL, Shore RE, Strax P, et al. (1995) A prospective study of endogenous estrogens and breast cancer in postmenopausal women. J. Natl. Cancer Inst. 87(3):190–197.Crossref, Google Scholar
• Trainer AH, Lewis CR, Tucker K, Meiser B, Friedlander M, Ward RL (2010) The role of BRCA mutation testing in determining breast cancer therapy. Nature Rev. Clinical Oncology 7(12):708–717.Crossref, Google Scholar
• van Gorp T, Cadron I, Despierre E, Daemen A, Leunen K, Amant F, Timmerman D, et al. (2011) HE4 and CA125 as a diagnostic test in ovarian cancer: Prospective validation of the Risk of Ovarian Malignancy Algorithm. British J. Cancer 104(5):863–870.Crossref, Google Scholar
• van Roosmalen MS, Verhoef LC, Stalmeier PF, Hoogerbrugge N, van Daal WA (2002) Decision analysis of prophylactic surgery or screening for BRCA1 mutation carriers: A more prominent role for oophorectomy. J. Clinical Oncology 20(8):2092–2100.Crossref, Google Scholar
• White CC, White DJ (1989) Markov decision processes. Eur. J. Oper. Res. 39(1):1–16.Crossref, Google Scholar
• Wooster R, Neuhausen S, Mangion J, Quirk Y, Ford D, Collins N, Nguyen K (1994) Localization of a breast cancer susceptibility gene, BRCA2, to chromosome 13q12-13. Science 265(5181):2088–2090.Crossref, Google Scholar
• World Cancer Research Fund International (2015) Cancer facts and figures—Worldwide data. Accessed June 15, 2017, http://www.wcrf.org/int/cancer-facts-figures/worldwide-data.Google Scholar